Publisher Correction: Author Correction: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial

Hongli Gong, Shu Tian, Hao Ding, Lei Tao, Li Wang, Jie Wang, Tian Wang, Xiaohui Yuan, Yu Heng, Ming Zhang, Yong Shi, Chengzhi Xu, Chunping Wu, Shengzi Wang () and Liang Zhou ()
Additional contact information
Hongli Gong: Fudan University
Shu Tian: Fudan University
Hao Ding: Fudan University
Lei Tao: Fudan University
Li Wang: Fudan University
Jie Wang: Fudan University
Tian Wang: Fudan University
Xiaohui Yuan: Fudan University
Yu Heng: Fudan University
Ming Zhang: Fudan University
Yong Shi: Fudan University
Chengzhi Xu: Fudan University
Chunping Wu: Fudan University
Shengzi Wang: Fudan University
Liang Zhou: Fudan University

Nature Communications, 2024, vol. 15, issue 1, 1-1

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52656-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52656-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52656-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().